GOPwinger Lies/Distortions/Omissions/Perversions of Truth Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : GOPwinger Lies/Distortions/Omissions/Perversions of Truth

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Kenneth E. Phillipps who wrote (110884)	12/10/2007 2:56:52 PM
From: DizzyG	of 173976

Wrong, again Kenneth... This research is privately funded. Pilot Transplantation Studies in Respiratory and Cardiovascular Disorders Funding: 2005 - 2008 Promising pre-clinical results developed by Dr. Duncan Stewart, a SCN-affiliated scientist, are now being translated into a novel therapy for patients with IPAH who are refractory to all currently available therapies, and therefore face a survival likely of less than one year. The intellectual property derived from this technology has been captured by a private Canadian biotech start-up Northern Therapeutics Inc (NTI). NTI has a Health-Canada approved clinical study in cellular therapeutics for treatment of primary pulmonary hypertension, and the SCN-CARENeT partnership will be a major component in clinical translation of this technology. Northern Therapeutics and CARENeT-funded scientists (Stewart and Galipeau) have signed a Memorandum of Understanding which will specifically seek to clinically translate within the first semester of funding cell-based therapies. The Pulmonary Hypertension And Cell Therapy (PHACeT) trial will study the safety of administration of eNOS-transfected autologous Endothelial Progenitor Cells in the setting of severe PAH, and represents the world's first gene or cell therapy clinical trial for this devastating disease, with a prognosis as bad as the worst malignancies. The PHACeT trial has received approval from Health Canada and is poised to start in Toronto and Montreal as soon institutional ethics approval is obtained. This trial provides a model of how advances in basic stem cell and gene therapy research can be translated innovative clinical therapies, that can be used for other disease targets such as myocardium. Establishment of enabling services and infrastructure - Partnering of SCN, NTI and the Montreal Jewish General Hospital (JGH). Our main objective is to implement and validate the clinical-grade cell handling process required of the PHACeT study in anticipation of patient recruitment. SCN funding serves to enable a clinical-grade cell handling facility for prosecution of Network-partnered clinical studies. A Memorandum of Understanding has been struck between the JGH and NTI. JGH provides privileged access to its cell processing center and also provides Directorship of process validation and HQP. NTI provides direct operating costs required of the facility to perform validation of protocol with cellular materials derived from at least 6 normal volunteers. NTI also provides cell handling protocol expertise. It is anticipated that patient recruitment would follow, tentatively in 2006. Like donated bone marrow, umbilical cord blood can be used to treat various genetic disorders that affect the blood and immune system. Commercial and non-commercial firms have emerged to provide services to parents to store their newborn's cord blood. This project includes an ELSI study (under the direction of Dr. Bartha Knoppers) to investigate the socio-ethical and legal issues related to umbilical cord blood banking, and the application of cord blood to stem cell therapy, in Canada. stemcellnetwork.ca So much for socialized medicine. More disingenuous posting from you. Diz-

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next